| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cytomx Therapeutics, Inc. (CTMX) has 12 insiders with recent SEC Form 4 filings, including 1 buy and 11 sells. CTMX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 987.9K | $3.90M | - | |
| Other | 650.0K | $2.56M | - | |
| CFO | 78.3K | $308.7K | - | |
| Other | 43.8K | $172.6K | - | |
| Dir | 38.0K | $149.9K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2022 | Campoy Carlos | Chief Financial Officer | Sell | 3,949 | $1.42 | $5,617.06 | -9.0% | -6.6% | +18.5% | |
| Jun 16, 2021 | McCarthy Sean A.69 | President And CEO | Sell | 100,000 | $7.04 | $704,470.00 | -51.8% | -29.9% | -76.9% | |
| Mar 31, 2021 | McCarthy Sean A.69 | President And CEO | Sale+OE | 100,000 | $7.49 | $749,470.00 | -32.6% | -16.3% | -65.5% | |
| May 12, 2020 | McCarthy Sean A.69 | President And CEO | Sale+OE | 36,000 | $15.00 | $540,000.00 | -29.9% | - | - | |
| Mar 4, 2019 | Rowland Lloyd A50 | General Counsel | Buy | 9,000 | $10.33 | $92,970.00 | +919.3% | - | - | |
| Dec 12, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $15.00 | $45,000.00 | -33.6% | - | - | |
| Nov 2, 2018 | McCarthy Sean A.69 | President And CEO | Sale+OE | 6,526 | $15.00 | $97,898.59 | -2.5% | - | - | |
| Nov 1, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $15.00 | $45,000.00 | -33.6% | - | - | |
| Oct 1, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $18.46 | $55,380.00 | -33.6% | - | - | |
| Sep 4, 2018 | Ray Debanjan | Chief Financial Officer | Sale+OE | 3,000 | $22.39 | $67,170.00 | -33.6% | - | - |